Recent Quotes (30 days)

You have no recent quotes
chg | %

Cardiome Pharma Corp.  

(Public, TSE:COM)   Watch this stock  
Find more results for COM
11.81
+0.01 (0.08%)
May 29 - Close
TSE data delayed by 15 mins - Disclaimer
Currency in CAD
Range 11.81 - 12.00
52 week 6.62 - 13.80
Open 11.84
Vol. 10,400.00
Mkt cap 196.43M
P/E     -
Div/yield     -
EPS -1.43
Shares 16.77M
Beta 0.83
Inst. own     -
Aug 10, 2015
Q2 2015 Cardiome Pharma Corp Earnings Release (Estimated) Add to calendar
Jun 16, 2015
Cardiome Pharma Corp Annual Shareholders Meeting (Estimated) - 11:30AM EDT - Add to calendar
May 13, 2015
Q1 2015 Cardiome Pharma Corp Earnings Call
May 13, 2015
Q1 2015 Cardiome Pharma Corp Earnings Release
Mar 12, 2015
Q4 2014 Cardiome Pharma Corp Earnings Call
Mar 12, 2015
Q4 2014 Cardiome Pharma Corp Earnings Release
  

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -70.71% -60.67%
Operating margin -48.34% -55.21%
EBITD margin - -48.05%
Return on average assets -33.61% -37.41%
Return on average equity -99.95% -91.63%
Employees 85 -
CDP Score - -

Address

1441 Creekside Dr 6th Floor
VANCOUVER, BC V6J 4S7
Canada
+1-604-6776905 (Phone)
+1-604-6776915 (Fax)

Website links

Description

Cardiome Pharma Corp. (Cardiome) is a Canada-based biopharmaceutical company. The Company is focused on the development and commercialization of cardiovascular therapies which improves the health of patients suffering from heart disease. Cardiome has two products that are marketed as in-hospital cardiology products, BRINAVESS and AGGRASTAT which are available in markets across the United States. BRINAVESS (vernakalant (IV)), is approved in the European Union and in approximately 50 countries for the rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults and for use in post-cardiac surgery patients with atrial fibrillation of three days or less. AGGRASTAT (tirofiban HCL) is a reversible GP IIb/IIIa inhibitor (an intravenous anti-platelet drug) for use in Acute Coronary Syndrome patients. Cardiome also has several pre-clinical projects directed at various therapeutic indications.

Officers and directors

Robert W. Rieder Chairman of the Board
Age: 68
William L. Hunter M.D. President, Chief Executive Officer, Director
Age: 50
Jennifer Archibald Chief Financial Officer
Sheila M. Grant Chief Operating Officer
David D. McMasters J.D. General Counsel
Richard M. Glickman Lead Independent Director
Age: 57
W. James O'Shea Director
Peter W. Roberts CPA Independent Director
Harold H. Shlevin Independent Director
Age: 65